{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:44:08Z","timestamp":1793375048217,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.critrevonc.2023.103924","type":"journal-article","created":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T09:37:36Z","timestamp":1674380256000},"page":"103924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Metaplastic breast cancer: A review"],"prefix":"10.1016","volume":"182","author":[{"given":"Horatio R.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Boyraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle I.","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1245\/s10434-014-3890-4","article-title":"Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis","volume":"22","author":"Nelson","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1245\/s10434-006-9124-7","article-title":"Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base","volume":"14","author":"Pezzi","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103924_bib3","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (accessed April 12, 2022."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-018-5005-6","article-title":"Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis","volume":"173","author":"He","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1245\/s10434-017-6316-2","article-title":"Metaplastic breast cancer: practice patterns, outcomes, and the role of radiotherapy","volume":"25","author":"Haque","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103924_bib6","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1245\/s10434-018-6533-3","article-title":"Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database","volume":"25","author":"Ong","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejso.2017.11.027","article-title":"Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis","volume":"44","author":"Zhao","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-017-4367-5","article-title":"Predictive factors on outcomes in metaplastic breast cancer","volume":"165","author":"Leyrer","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103924_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/000313480507100906","article-title":"Metaplastic breast cancer: clinical features and outcomes","volume":"71","author":"Gibson","year":"2005","journal-title":"Am. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ajcp\/96.6.781","article-title":"Metaplastic carcinomas and sarcomas of the breast","volume":"96","author":"Wargotz","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3349\/ymj.2010.51.6.864","article-title":"Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast","volume":"51","author":"Park","year":"2010","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.critrevonc.2023.103924_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3389\/fonc.2019.00747","article-title":"The effect of post-mastectomy radiotherapy in patients with metaplastic breast cancer: an analysis of SEER database","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2214\/AJR.07.2056","article-title":"Imaging differences in metaplastic and invasive ductal carcinomas of the breast","volume":"189","author":"Yang","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1258\/ar.2011.110341","article-title":"Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment","volume":"53","author":"Choi","year":"2012","journal-title":"Acta Radiol."},{"issue":"1064","key":"10.1016\/j.critrevonc.2023.103924_bib15","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140644","article-title":"Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases","volume":"89","author":"Langlands","year":"2016","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2214\/ajr.184.4.01841274","article-title":"MRI of metaplastic carcinoma of the breast","volume":"184","author":"Velasco","year":"2005","journal-title":"AJR Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103924_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/0046-8177(89)90149-4","article-title":"Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma","volume":"20","author":"Wargotz","year":"1989","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/1097-0142(19900115)65:2<272::AID-CNCR2820650215>3.0.CO;2-6","article-title":"Metaplastic carcinomas of the breast. IV.\u00a0Squamous cell carcinoma of ductal origin","volume":"65","author":"Wargotz","year":"1990","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103924_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0046-8177(89)90065-8","article-title":"Metaplastic carcinomas of the breast. II. Spindle cell carcinoma","volume":"20","author":"Wargotz","year":"1989","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/his.13159","article-title":"Immunoprofile of metaplastic carcinomas of the breast","volume":"70","author":"Rakha","year":"2017","journal-title":"Histopathology"},{"issue":"16","key":"10.1016\/j.critrevonc.2023.103924_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-0108","article-title":"Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component","volume":"23","author":"Avigdor","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.103924_bib22","unstructured":"Board WCoTE. Metaplastic carcinoma. WHO Classification of Tumours: Breast Tumours. 5th Edition ed; 2019: 134\u2013138."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103924_bib23","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.5858\/arpa.2019-0396-RA","article-title":"Metaplastic breast carcinoma: update on histopathology and molecular alterations","volume":"143","author":"McMullen","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41467-020-15283-z","article-title":"Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors","volume":"11","author":"Djomehri","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103924_bib25","first-page":"12","article-title":"Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma","author":"Gonzalez-Martinez","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103924_bib26","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-3441","article-title":"Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics","volume":"69","author":"Hennessy","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-016-3718-y","article-title":"Whole exome sequencing of rare aggressive breast cancer histologies","volume":"156","author":"Dieci","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2023.103924_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.humpath.2018.11.023","article-title":"Molecular characterization of metaplastic breast carcinoma via next-generation sequencing","volume":"86","author":"Zhai","year":"2019","journal-title":"Hum. Pathol."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.103924_bib29","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-16-2857","article-title":"The landscape of somatic genetic alterations in metaplastic breast carcinomas","volume":"23","author":"Ng","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103924_bib30","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1158\/0008-5472.CAN-04-4009","article-title":"PED mediates AKT-dependent chemoresistance in human breast cancer cells","volume":"65","author":"Stassi","year":"2005","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2023.103924_bib31","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","article-title":"HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells","volume":"22","author":"Knuefermann","year":"2003","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103924_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41379-018-0081-z","article-title":"Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma","volume":"31","author":"Krings","year":"2018","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103924_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jclinpath-2016-203874","article-title":"Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1","volume":"70","author":"Joneja","year":"2017","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103924_bib36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5858\/arpa.2014-0200-OA","article-title":"Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options","volume":"139","author":"Ross","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103924_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-01065-3","article-title":"Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1","volume":"123","author":"Kalaw","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-017-4161-4","article-title":"Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer","volume":"163","author":"Yeong","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2016.06.002","article-title":"Management and outcomes in metaplastic breast cancer","volume":"16","author":"Tzanninis","year":"2016","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/gs.2018.01.01","article-title":"Management of the axilla in metaplastic breast carcinoma","volume":"7","author":"Murphy","year":"2018","journal-title":"Gland Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib43","first-page":"2112","article-title":"Metaplastic breast carcinoma: a clinical analysis of 26 cases","volume":"11","author":"Jin","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103924_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clbc.2017.04.009","article-title":"Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature","volume":"17","author":"El Zein","year":"2017","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib45","first-page":"193","article-title":"Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast","volume":"180","author":"Gutman","year":"1995","journal-title":"J. Am. Coll. Surg."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103924_bib46","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2170::AID-CNCR11>3.0.CO;2-X","article-title":"Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence","volume":"85","author":"Gobbi","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib47","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clbc.2014.10.002","article-title":"Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07)","volume":"15","author":"Yu","year":"2015","journal-title":"Clin. Breast Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/ajcp\/aqv097","article-title":"A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma","volume":"145","author":"Cimino-Mathews","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2023.103924_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211004889","article-title":"Metaplastic breast carcinoma: experience of a tertiary cancer center in the middle east","volume":"28","author":"Erjan","year":"2021","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1245\/s10434-010-1198-6","article-title":"Metaplastic breast cancer: to radiate or not to radiate?","volume":"18","author":"Tseng","year":"2011","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib51","doi-asserted-by":"crossref","DOI":"10.7150\/jca.40817","article-title":"Outcomes after treatment of metaplastic versus other breast cancer subtypes","volume":"11","author":"Moreno","year":"2020","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103924_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131409","article-title":"Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","article-title":"Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer","volume":"120","author":"Jung","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1008329910362","article-title":"Metaplastic breast cancer: prognosis and response to systemic therapy","volume":"10","author":"Rayson","year":"1999","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5858\/arpa.2020-0830-OA","article-title":"Clinicopathologic characteristics and outcome descriptors of metaplastic breast carcinoma","volume":"146","author":"Abada","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.critrevonc.2023.103924_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2019.10.003","article-title":"Comparison of outcomes between metaplastic and triple-negative breast cancer patients","volume":"49","author":"Polamraju","year":"2020","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10549-019-05264-2","article-title":"Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy","volume":"176","author":"Al-Hilli","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.103924_bib58","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-18-0585","article-title":"Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel","volume":"24","author":"Sharma","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-011-1686-9","article-title":"Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era","volume":"130","author":"Chen","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103924_bib60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/tbj.13234","article-title":"Metaplastic carcinoma of the breast: prognosis and response to systemic treatment in metastatic disease","volume":"25","author":"Takala","year":"2019","journal-title":"Breast J."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103924_bib61","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1245\/s10434-014-3782-7","article-title":"Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas","volume":"21","author":"Wright","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103924_bib62","article-title":"Response to dabrafenib and trametinib of a patient with metaplastic breast carcinoma harboring a BRAF V600E mutation","volume":"2020","author":"Seo","year":"2020","journal-title":"Case Rep. Oncol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-020-0846-y","article-title":"Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers","volume":"13","author":"Coussy","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103924_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","article-title":"Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mtor inhibition in combination with liposomal doxorubicin and bevacizumab","volume":"3","author":"Basho","year":"2017","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103924_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226464","article-title":"Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor","volume":"15","author":"Chang","year":"2020","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.critrevonc.2023.103924_bib66","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1073\/pnas.1500223112","article-title":"Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer","volume":"112","author":"Henneman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2023.103924_bib67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-017-0011-0","article-title":"Dramatic response of metaplastic breast cancer to chemo-immunotherapy","volume":"3","author":"Adams","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2023.103924_bib68","article-title":"A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1159\/000515510","article-title":"Durable response to PD1 inhibitor pembrolizumab in a metastatic, metaplastic breast cancer","volume":"14","author":"Gorshein","year":"2021","journal-title":"Case Rep. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103924_bib70","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103924_bib71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103924_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1477-7819-11-129","article-title":"Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators","volume":"11","author":"Song","year":"2013","journal-title":"World J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103924_bib73","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.7314\/APJCP.2012.13.9.4645","article-title":"Metaplastic breast carcinoma: case series and review of the literature","volume":"13","author":"Esbah","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-011-1393-6","article-title":"Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers","volume":"131","author":"Lester","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103924_bib75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjsurg.2006.01.038","article-title":"Metaplastic breast cancer: clinical significance","volume":"191","author":"Beatty","year":"2006","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.critrevonc.2023.103924_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12885-015-1079-2","article-title":"Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors","volume":"15","author":"Barquet-Munoz","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103924_bib77","doi-asserted-by":"crossref","first-page":"22070","DOI":"10.1038\/s41598-020-79166-5","article-title":"The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma","volume":"10","author":"Wu","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103924_bib78","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00000478-198705000-00003","article-title":"Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma","volume":"11","author":"Rosen","year":"1987","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2023.103924_bib79","unstructured":"Yam C. Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative. October 28, 2014 ed."},{"key":"10.1016\/j.critrevonc.2023.103924_bib80","unstructured":"Goetz M.P. Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer. June 7, 2019 ed."},{"key":"10.1016\/j.critrevonc.2023.103924_bib81","unstructured":"Niravath P.A. L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients. July 15, 2016."},{"key":"10.1016\/j.critrevonc.2023.103924_bib82","unstructured":"Pharmaceuticals A. A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY). July 8, 2020 ed."},{"key":"10.1016\/j.critrevonc.2023.103924_bib83","unstructured":"Ruddy K.J. , 2017. Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer. January 6, 2017 ed."},{"key":"10.1016\/j.critrevonc.2023.103924_bib84","unstructured":"Patel S.P. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors. July 15, 2016 ed."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:46:28Z","timestamp":1760903188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":84,"alternative-id":["S1040842823000124"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103924","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metaplastic breast cancer: A review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103924"}}